Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (4): 313-317.doi: 10.3969/j.issn.1000-6621.2021.04.003
• Expert Note • Previous Articles Next Articles
Received:
2021-02-26
Online:
2021-04-10
Published:
2021-04-09
Contact:
GAO Wei-wei
E-mail:gwwjys@sina.com
MA Yan*, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317. doi: 10.3969/j.issn.1000-6621.2021.04.003
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.04.003
[1] | 中华人民共和国卫生部疾病预防控制局, 中华人民共和国卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 中国协和医科大学出版社, 2009: 52-70. |
[2] | World Health Organization. Global Tuberculosis Report 2019. Geneva: World Health Organization, 2019. |
[3] |
Jones-López EC, Ayakaka I, Levin J, et al. Effectiveness of the standard WHO recommended retreatment regimen (category Ⅱ) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med, 2011,8(3):e1000427. doi: 10.1371/journal.pmed.1000427.
doi: 10.1371/journal.pmed.1000427 URL pmid: 21423586 |
[4] |
Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J, 2005,25:928-936. doi: 10.1183/09031936.05.00103004.
doi: 10.1183/09031936.05.00103004 URL pmid: 15863653 |
[5] | World Health Organization Regional Office for Europe. Treatment of tuberculosis. 3rd ed. Geneva: World Health Organization, 2003. |
[6] |
Nakanwagi-Mukwaya A, Reid AJ, Fujiwara PI, et al. Characteristics and treatment outcomes of tuberculosis retreatment cases in three regional hospitals, Uganda. Public Health Action, 2013,3(2):149-155. doi: 10.5588/pha.12.0105.
doi: 10.5588/pha.12.0105 URL pmid: 26393019 |
[7] |
Ottmani SE, Zignol M, Bencheikh N, et al. Results of cohort analysis by category of tuberculosis retreatment cases in Morocco from 1996 to 2003. Int J Tuberc Lung Dis, 2006,10(12):1367-1372.
URL pmid: 17167954 |
[8] |
Tabarsi P, Chitsaz E, Tabatabaei V, et al. Revised category Ⅱ regimen as an alternative strategy for retreatment of category Ⅰ regimen failure and irregular treatment cases. Am J Ther, 2011,18(5):343-349. doi: 10.1097/MJT.0b013e3181dd60ec.
doi: 10.1097/MJT.0b013e3181dd60ec URL pmid: 20535008 |
[9] |
Acuña-Villaorduña C, Ayakaka I, Dryden-Peterson S, et al. High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. Am J Trop Med Hyg, 2015,93(1):73-75. doi: 10.4269/ajtmh.14-0810.
doi: 10.4269/ajtmh.14-0810 URL pmid: 25940196 |
[10] | 符彩云, 符致顺. 1500例复治涂阳肺结核成因及疗效分析. 中国防痨杂志, 2000,22(2):91-92. |
[11] | 全国肺结核短化协作组. 肺结核短程化疗的研究. 中华结核和呼吸系疾病杂志, 1982,5(2):78-81. |
[12] | 全国肺结核短化协作组. 第二批肺结核短程化疗研究初报. 中华结核和呼吸系疾病杂志, 1984,7(4):198-202. |
[13] | 唐神结, 李亮. 临床医务人员结核病防治培训教材. 北京: 人民卫生出版社, 2019:27. |
[14] | 万利亚, 武桂英, 龚幼龙, 等. 结核病管理策略对复治原因的影响研究. 中国防痨杂志, 2003,25(6):347-350. |
[15] | 中华人民共和国卫生部. 全国结核病耐药基线调查报告(2007—2008年). 北京: 人民卫生出版社, 2010:49. |
[16] | 中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001. |
[17] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[18] | World Health Organization Regional Office for Europe. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization, 2016. |
[19] | World Health Organization Regional Office for Europe. Guidelines for treatment of drugsusceptible tuberculosis and patient care. Geneva: World Health Organization, 2017. |
[20] | 朱莉贞, 高孟秋, 陈巍, 等. 复治肺结核化疗新方案与原复治方案的临床对照研究. 中国防痨杂志, 2012,34(5):304-309. |
[21] |
Zhou C, Jiang W, Yuan L, et al. Access to Bacteriologic-Based Diagnosis in Smear Positive Retreatment Tuberculosis Patients in Rural China: A Cross-Sectional Study in Three Geographic Varied Provinces. PLoS One, 2016,11(1):e0146340. doi: 10.1371/journal.pone.0146340.
doi: 10.1371/journal.pone.0146340 URL pmid: 26751583 |
[22] |
Wang XM, Yin SH, Du J, et al. Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model. Epidemiol Infect, 2017,145(9):1805-1814. doi: 10.1017/S0950268817000656.
doi: 10.1017/S0950268817000656 URL pmid: 28397611 |
[23] | 杨新宇, 易俊莉, 邢青, 等. 881例疑似耐多药肺结核患者的耐药性分析. 中国防痨杂志, 2018,40(2):183-188. doi: 10.3969/j.issn.1000-6621.2018.02.014. |
[24] | 杨安文, 周亮, 徐祖辉, 等. 湖南省肺结核四种一线抗结核药物耐药特征及影响因素研究. 中国人兽共患病学报, 2018,34(5):396-403. doi: 10.3969/j.issn.1002-2694.2018.00.074. |
[25] |
Abdella K, Abdissa K, Kebede W, et al. Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. BMC Public Health, 2015,15:599. doi: 10.1186/s12889-015-1955-3.
doi: 10.1186/s12889-015-1955-3 URL pmid: 26135909 |
[26] | 杜建, 高微微, 马艳, 等. 优化方案和规范化方案对复治肺结核合并糖尿病的疗效. 中华结核和呼吸杂志, 2015,38(12):886-891. doi: 10.3760/cma.j.issn.1001-0939.2015.12.003. |
[27] | 沙巍, 张青, 崔文玉, 等. 首次复治肺结核患者短程化疗新方案的临床研究. 中国防痨杂志, 2017,39(1):39-45. doi: 10.3969/j.issn.1000-6621.2017.01.011. |
[28] | 杜建, 刘宇红, 李亮, 等. 复治肺结核患者采用不同化疗方案的效果评价. 中国防痨杂志, 2016,38(10):850-857. doi: 10.3969/j.issn.1000-6621.2016.10.013. |
[29] |
Sander MS, Vuchas CY, Numfor HN, et al. Sputum bacterial load predicts multidrug-resistant tuberculosis in retreatment patients: a case-control study. Int J Tuberc Lung Dis, 2016,20(6):793-799. doi: 10.5588/ijtld.15.0259.
doi: 10.5588/ijtld.15.0259 URL pmid: 27155183 |
[30] |
Akhtar AM, Arif MA, Kanwal S, et al. Prevalence and drug resistance pattern of MDR TB in retreatment cases of Punjab, Pakistan. J Pak Med Assoc, 2016,66(8):989-993.
URL pmid: 27524534 |
[31] |
Cohen DB, Meghji J, Squire SB. A systematic review of clinical outcomes on the WHO Category Ⅱ retreatment regimen for tuberculosis. Int J Tuberc Lung Dis, 2018,22(10):1127-1134. doi: 10.5588/ijtld.17.0705.
URL pmid: 30236179 |
[32] | 巫株华, 黎贞燕, 李宇轩, 等. 广东省2911例涂阳肺结核病患者的耐药疫情分析. 广东医学, 2018,39(2):228-234. doi: 10.3969/j.issn.1001-9448.2018.02.016. |
[33] |
Li Q, Zhao G, Wu L, et al. Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. Antimicrob Resist Infect Control, 2018,7:61. doi: 10.1186/s13756-018-0348-7.
doi: 10.1186/s13756-018-0348-7 URL pmid: 29744042 |
[34] | 戈启萍, 杜建, 姜广路, 等. 标准复治化疗方案治疗多耐药及敏感复治肺结核患者的对比研究. 中国防痨杂志, 2015,37(8):879-884. doi: 10.3969/j.issn.1000-6621.2015.08.017. |
[35] |
Lee H, Ahn S, Hwang NY, et al. Limited effect of later-generation fluoroquinolones in the treatment of ofloxacin-resistant and moxifloxacin-susceptible multidrug-resistant tuberculosis. Antimicrob Agents Chemother, 2018,62(2):e01784-17. doi: 10.1128/AAC.01784-17.
doi: 10.1128/AAC.01784-17 URL pmid: 29203478 |
[36] |
Ndjeka N, Schnippel K, Master I, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J, 2018,52(6):1801528. doi: 10.1183/13993003.01528-2018.
doi: 10.1183/13993003.01528-2018 URL pmid: 30361246 |
[37] | 杜建, 韩喜琴, 舒薇, 等. 复治菌阳肺结核患者治疗成功后再次复发的危险因素分析. 中国防痨杂志, 2019,41(6):624-631. doi: 10.3969/j.issn.1000-6621.2019.06.007. |
[38] |
Velayati AA, Farnia P, Ibrahim TA, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy, 2009,55(5):303-307. doi: 10.1159/000226425.
doi: 10.1159/000226425 URL pmid: 19556787 |
[39] |
Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis, 2010,10(2):103-111. doi: 10.1016/S1473-3099(09)70330-5.
URL pmid: 20113979 |
[40] | 中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469. doi: 10.3969/j.issn.1000-6621.2015.05.001. |
[41] | World Health Organization Regional Office for Europe. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization, 2018 |
[42] | World Health Organization Regional Office for Europe. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization, 2018. |
[43] | 黄学锐, 高微微, 张旭霞, 等. 氧氟沙星和左氧氟沙星抗结核分枝杆菌临床耐药界限的研究. 中华结核和呼吸杂志, 2004,27(2):84-88. |
[44] | 张旭霞, 王苏民, 高微微. 三种喹诺酮类药物抗结核分支杆菌最低抑菌浓度分布状况研究. 中国防痨杂志, 2001,23(4):222-224. |
[45] |
Silva TC, Matsuoka PDFS, Aquino DMC, et al. Factors associated with tuberculosis retreatment in priority districts of Maranhão, Brazil. Cien Saude Colet, 2017,22(12):4095-4104. doi: 10.1590/1413-812320172212.20612015.
doi: 10.1590/1413-812320172212.20612015 URL pmid: 29267726 |
[46] |
Zheng C, Li S, Luo Z, et al. Mixed Infections and Rifampin Heteroresistance among Mycobacterium tuberculosis Clinical Isolates. J Clin Microbiol, 2015,53(7):2138-2147. doi: 10.1128/JCM.03507-14.
doi: 10.1128/JCM.03507-14 URL pmid: 25903578 |
[47] | 陈燕琴, 杜建, 刘宇红, 等. 住院肺结核患者体重与口服异烟肼剂量的关系. 中华结核和呼吸杂志, 2018,41(7):529-533. doi: 10.3760/cma.j.issn.1001-0939.2018.07.005. |
[48] | Chen L, Du J, Li L, et al. Low doses of rifampicin used in new tuberculosis patients correlated to increased frequency of rifampicin-resistance and poorer treatment outcomes. Open Journal of Medical Microbiology, 2015,5(2):76-84. doi: 10.4236/ojmm.2015.52009. |
[49] | 杜建, 钟球, 傅衍勇, 等. 复治肺结核患者初治时使用利福类药物剂量的调查. 中国防痨杂志, 2016,38(1):42-46. doi: 10.3969/j.issn.1000-6621.2016.01.010. |
[50] |
Prahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother, 2015,70(1):321-322. doi: 10.1093/jac/dku373.
doi: 10.1093/jac/dku373 URL pmid: 25246439 |
[51] | 孙晓方, 严文, 任裴, 等. 442例异烟肼血药浓度监测结果分析. 中国防痨杂志, 2015,37(11):1136-1140. doi: 10.3969/j.issn.1000-6621.2015.11.011. |
[52] | 魏香兰, 方如塘, 师延峰, 等. 抗结核药物的血药浓度监测结果分析. 中国医院药学杂志, 2015,35(21):1918-1921. doi: 10.13286/j.cnki.chinhosppharmacyj.2015.21.08. |
[1] | DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321. |
[2] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[3] | GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334. |
[4] | ZHANG Li-jie*, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340. |
[5] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui, LI Cheng-cheng. Analysis of CT features of drug-resistant pulmonary tuberculosis with cavity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 341-345. |
[6] | YU Shan, LI Zhi-ming, XU Chun-xia, WANG Tao. Analysis of risk factors associated with false negative results of interferon-gamma release assays on peripheral blood from tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 346-351. |
[7] | LIU Ting*, WANG Liang, YANG Mei. The study on the anti-tuberculosis activity of polymorphonuclear cell from peripheral blood of patients with multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 352-356. |
[8] | ZHANG Chen-chen*, TAN Wei-guo, GUO Hui-xin, HUANG Xin-chun, CHEN Yan-mei, WEI Wen-jing. The effect of Mycobacterium tuberculosis infection on sputum flora structure [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 357-363. |
[9] | BAI Hua, GUO Jing-wei, HU Pei-lei, YI Song-lin, WEN Jia, LIU Feng-ping, TAN Yun-hong, BAI Li-qiong. Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Hu’nan Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 364-369. |
[10] | WANG Huan*, SHEN Xin, CHEN Jing, XIA Zhen, XU Biao, YUAN Zheng-an. Analysis of the epidemiological characteristics of pulmonary tuberculosis among migrants in Shanghai from 2008 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 370-377. |
[11] | MA Zhi-tao, WANG Na, LYU Yang, HU Wei-hong, CHEN Chang, HE Fan, SHEN Xin, LIU Xiao-feng. The research on psychological status of pulmonary tuberculosis patients and influencing factors in Baoshan District, Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 378-384. |
[12] | LI Zhi-hong, GU Kan-kai, YAO Jing, ZHANG Huai-qing, HAN Zhi-ying, SHEN Xin, CHEN Jing, SHEN Bing. Analysis of screening of close contacts of a tuberculosis patient in a kindergarten in downtown Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 385-390. |
[13] | Maiweilanjiang· Abulimiti, Diermulati· Tusun, LIU Zhen-jiang, Xirizhati· Mamuti, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[14] | ZHOU Shuang, CHEN Nan, ZHU Kun, JIANG Hui, YANG Lei, DU Jian. Investigation of the experience of tuberculosis patients for follow up using the internet platform [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 398-403. |
[15] | CAO Xiao-man, LIU Wei, LIU Tao, WANG Chun, GAO Guang-kuo, ZHAI Wen-ting, CHEN Fen, WU Chun-yu. Analysis of the effect of flurbiprofen axetil on postoperative fever in patients with spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 409-412. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||